亚砷酸-铂（II）抗癌配合物水溶液的稳定结构与反应活性
Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes.
作者信息
Miodragović Đenana U, Quentzel Jeremy A, Kurutz Josh W, Stern Charlotte L, Ahn Richard W, Kandela Irawati, Mazar Andrew, O'Halloran Thomas V
机构信息
Chemistry of Life Processes Institute and Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208 (USA) http://www.chemistry.northwestern.edu/faculty/thomas-ohalloran.html.
出版信息
Angew Chem Int Ed Engl. 2013 Oct 4;52(41):10749-52. doi: 10.1002/anie.201303251. Epub 2013 Aug 22.
Abstract
The first molecular adducts of platinum and arsenic based anticancer drugs - arsenoplatins - show unanticipated structure, substitution chemistry, and cellular cytotoxicity. The Pt-As bonds in these complexes are stable in aqueous solution and strongly influence the lability of the ligand.
摘要
铂和砷基抗癌药物的首个分子加合物——砷铂化合物——展现出意想不到的结构、取代化学性质及细胞毒性。这些络合物中的铂-砷键在水溶液中稳定，且对配体的活性有强烈影响。
相似文献
1
Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes.亚砷酸-铂（II）抗癌配合物水溶液的稳定结构与反应活性
Angew Chem Int Ed Engl. 2013 Oct 4;52(41):10749-52. doi: 10.1002/anie.201303251. Epub 2013 Aug 22.
2
Potent anticancer activity and possible low toxicity of platinum(II) complexes with functionalized 1,1-cyclobutanedicarboxylate as a leaving ligand.以功能化的1,1-环丁烷二羧酸酯作为离去配体的铂（II）配合物具有强大的抗癌活性及可能的低毒性。
Chemistry. 2014 Nov 10;20(46):15216-25. doi: 10.1002/chem.201404090. Epub 2014 Sep 26.
3
Mixed ligand complexes of platinum(II) and palladium(II) with cytokinin-derived compounds Bohemine and Olomoucine: X-ray structure of [Pt(BohH+-N7)Cl(3)].9/5H2O [Boh=6-(benzylamino)-2-[(3-(hydroxypropyl)-amino]-9-isopropylpurine, Bohemine].铂（II）和钯（II）与细胞分裂素衍生化合物波希米宁和奥洛莫辛的混合配体配合物：[Pt（BohH⁺-N7）Cl（3）].9/5H2O [Boh = 6-（苄基氨基）-2-[(3-（羟丙基）-氨基]-9-异丙基嘌呤，波希米宁]的X射线结构
J Inorg Biochem. 2003 Apr 1;94(4):307-16. doi: 10.1016/s0162-0134(03)00051-5.
4
Design, Synthesis of Novel Platinum(II) Glycoconjugates, and Evaluation of Their Antitumor Effects.新型铂（II）糖缀合物的设计、合成及其抗肿瘤效果评估。
Chem Biol Drug Des. 2016 Jun;87(6):867-77. doi: 10.1111/cbdd.12718. Epub 2016 Jan 29.
5
Homo- and heteroleptic Pt(II) complexes of ONN donor hydrazone and 4-picoline: A synthetic, structural and detailed mechanistic anticancer investigation.ONN 供体腙和 4-吡啶基同系物和异种 Pt(II)配合物：合成、结构和详细的抗癌机制研究。
Eur J Med Chem. 2018 Jan 1;143:1039-1052. doi: 10.1016/j.ejmech.2017.11.044. Epub 2017 Nov 26.
6
Novel oximato-bridged platinum(II) di- and trimer(s): synthetic, structural, and in vitro anticancer activity studies.新型氧桥联铂(II)二聚体和三聚体的合成、结构及体外抗癌活性研究。
Inorg Chem. 2012 Jul 2;51(13):7153-63. doi: 10.1021/ic300148e. Epub 2012 Jun 12.
7
Anticancer platinum(II) complexes bearing N-heterocycle rings.含氮杂环的抗癌铂（II）配合物。
Bioorg Med Chem Lett. 2019 Jun 1;29(11):1257-1263. doi: 10.1016/j.bmcl.2019.03.045. Epub 2019 Mar 29.
8
Morpholine or methylpiperazine and salicylaldimine based heteroleptic square planner platinum (II) complexes: In vitro anticancer study and growth retardation effect on E. coli.吗啉或甲基哌嗪与水杨醛亚胺基的杂配体平面正方形铂（II）配合物：体外抗癌研究及对大肠杆菌的生长抑制作用
Eur J Med Chem. 2017 May 5;131:263-274. doi: 10.1016/j.ejmech.2017.03.014. Epub 2017 Mar 18.
9
Target-selective delivery and activation of platinum-based anticancer agents.铂基抗癌药物的靶向选择性递送与激活
Future Med Chem. 2015;7(7):911-27. doi: 10.4155/fmc.15.37.
10
trans-Dichloridopalladium(II) and platinum(II) complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine: synthesis, structural characterization, DNA binding and in vitro cytotoxicity studies.反式-二氯二钯(II)和铂(II)配合物与 2-(羟甲基)吡啶和 2-(2-羟乙基)吡啶的合成、结构表征、DNA 结合及体外细胞毒性研究。
Eur J Med Chem. 2013 Feb;60:386-94. doi: 10.1016/j.ejmech.2012.12.002. Epub 2012 Dec 8.
引用本文的文献
1
A Tunable Hydrogel Platform Based on Platinum-Containing Polymeric Arsenicals.基于含铂聚合砷化物的可调节水凝胶平台
Chem Mater. 2025 May 7;37(10):3733-3746. doi: 10.1021/acs.chemmater.5c00184. eCollection 2025 May 27.
2
Description of a Non-Canonical AsPt Blue Species Originating from the Aerobic Oxidation of AP-1 in Aqueous Solution.描述一种非典型的 AsPt 蓝物种，它源自水溶液中 AP-1 的需氧氧化。
Int J Mol Sci. 2024 Jul 5;25(13):7408. doi: 10.3390/ijms25137408.
3
An unprecedented palladium-arsenic catalytic cycle for nitriles hydration.一种前所未有的用于腈水合反应的钯-砷催化循环。
Front Chem. 2023 Aug 7;11:1253008. doi: 10.3389/fchem.2023.1253008. eCollection 2023.
4
Carbohydrate-conjugated 4-(1,3,2-dithiarsolan-2-yl)aniline as a cytotoxic agent against colorectal cancer.碳水化合物共轭的4-(1,3,2-二硫砷杂环戊烷-2-基)苯胺作为一种抗结直肠癌的细胞毒性剂。
RSC Adv. 2018 Dec 5;8(71):40760-40764. doi: 10.1039/c8ra07860b. eCollection 2018 Dec 4.
5
Preparation and characterization of erythrocyte membrane cloaked PLGA/arsenic trioxide nanoparticles and evaluation of their anti-tumor effect.红细胞膜包覆的聚乳酸-羟基乙酸共聚物/三氧化二砷纳米粒的制备、表征及其抗肿瘤效果评价
RSC Adv. 2018 Jun 1;8(36):20068-20076. doi: 10.1039/c8ra01417e. eCollection 2018 May 30.
6
Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy.纳米药物递送三氧化二砷用于增强肿瘤治疗的研究进展
Pharmaceutics. 2022 Mar 30;14(4):743. doi: 10.3390/pharmaceutics14040743.
7
Metallodrugs: Mechanisms of Action, Molecular Targets and Biological Activity.金属药物：作用机制、分子靶标和生物学活性。
Int J Mol Sci. 2022 Mar 23;23(7):3504. doi: 10.3390/ijms23073504.
8
Arsenic in medicine: past, present and future.医学中的砷：过去、现在和未来。
Biometals. 2023 Apr;36(2):283-301. doi: 10.1007/s10534-022-00371-y. Epub 2022 Feb 21.
9
Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study.砷铂-1 与蛋白质靶标的反应：实验与理论的综合研究。
Inorg Chem. 2022 Feb 21;61(7):3240-3248. doi: 10.1021/acs.inorgchem.1c03732. Epub 2022 Feb 9.
10
Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers.砷铂类碘化物类似物——三阴性乳腺癌的潜在候选药物。
Molecules. 2021 Sep 6;26(17):5421. doi: 10.3390/molecules26175421.
本文引用的文献
1
Trans-platinum/thiazole complex interferes with Sp1 zinc-finger protein.反式铂/噻唑复合物干扰Sp1锌指蛋白。
Angew Chem Int Ed Engl. 2012 Dec 3;51(49):12258-62. doi: 10.1002/anie.201206596. Epub 2012 Nov 4.
2
Redox activation of metal-based prodrugs as a strategy for drug delivery.基于氧化还原的金属前药激活策略用于药物递送。
Adv Drug Deliv Rev. 2012 Aug;64(11):993-1004. doi: 10.1016/j.addr.2012.01.007. Epub 2012 Jan 25.
3
The status of platinum anticancer drugs in the clinic and in clinical trials.铂类抗癌药物在临床和临床试验中的地位。
Dalton Trans. 2010 Sep 21;39(35):8113-27. doi: 10.1039/c0dt00292e. Epub 2010 Jun 30.
4
Arsenic trioxide - An old drug rediscovered.三氧化二砷——一种被重新发现的老药。
Blood Rev. 2010 Jul-Sep;24(4-5):191-9. doi: 10.1016/j.blre.2010.04.001. Epub 2010 May 15.
5
Targeting mitochondria for cancer therapy.针对线粒体的癌症治疗方法。
Nat Rev Drug Discov. 2010 Jun;9(6):447-64. doi: 10.1038/nrd3137. Epub 2010 May 14.
6
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.三氧化二砷通过直接结合 PML 来控制 PML-RARα 癌蛋白的命运。
Science. 2010 Apr 9;328(5975):240-3. doi: 10.1126/science.1183424.
7
Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment.用于靶向癌症治疗的砷基和铂基药物的共包封
Angew Chem Int Ed Engl. 2009;48(49):9295-9. doi: 10.1002/anie.200903655.
8
Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.三氧化二砷和顺铂协同作用增加人卵巢癌细胞的细胞毒性：卵巢癌的治疗潜力。
Cancer Sci. 2009 Dec;100(12):2459-64. doi: 10.1111/j.1349-7006.2009.01340.x. Epub 2009 Sep 2.
9
Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.三氧化二砷通过诱导细胞凋亡与顺铂对非小细胞肺癌细胞产生协同作用。
J Exp Clin Cancer Res. 2009 Aug 8;28(1):110. doi: 10.1186/1756-9966-28-110.
10
Biological responses to arsenic compounds.对砷化合物的生物学反应。
J Biol Chem. 2009 Jul 10;284(28):18583-7. doi: 10.1074/jbc.R900003200. Epub 2009 Apr 10.
Zotero 插件